Brokerages Set Korro Bio, Inc. (NASDAQ:KRRO) Target Price at $142.17

Shares of Korro Bio, Inc. (NASDAQ:KRRO) have received a consensus rating of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $142.17.

Several equities research analysts have recently issued reports on KRRO shares. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Korro Bio in a research note on Friday, November 22nd. William Blair reaffirmed an “outperform” rating on shares of Korro Bio in a research note on Wednesday, November 13th. Raymond James started coverage on Korro Bio in a research note on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price objective for the company. Finally, Royal Bank of Canada raised their price objective on Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, October 21st.

Insiders Place Their Bets

In other news, CFO Vineet Agarwal sold 800 shares of Korro Bio stock in a transaction on Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. 5.40% of the stock is currently owned by company insiders.

Institutional Trading of Korro Bio

A number of institutional investors have recently made changes to their positions in the business. Brown Brothers Harriman & Co. acquired a new stake in shares of Korro Bio in the 2nd quarter worth $28,000. Quest Partners LLC lifted its position in Korro Bio by 172.1% during the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after acquiring an additional 1,124 shares during the period. MetLife Investment Management LLC lifted its position in Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock worth $122,000 after acquiring an additional 2,050 shares during the period. Vestcor Inc acquired a new stake in Korro Bio during the 3rd quarter worth about $100,000. Finally, Lynx1 Capital Management LP acquired a new stake in Korro Bio during the 2nd quarter worth about $129,000. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Stock Up 6.6 %

NASDAQ KRRO opened at $46.88 on Tuesday. The business has a 50-day moving average price of $54.80 and a 200-day moving average price of $46.14. Korro Bio has a twelve month low of $30.00 and a twelve month high of $98.00.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.26) EPS for the quarter, beating analysts’ consensus estimates of ($2.55) by $0.29. Sell-side analysts forecast that Korro Bio will post -9.63 EPS for the current year.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).